Eversept Partners, LP Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001697013

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidFocusedHealth TiltHigh Turnover how tags are computed

Q2 2024 · 74 positions · Total reported value $1.46B · Top-10 concentration 61.2% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 66.4% · 29 new · 41 cut · 27 exited

Active Share (vs S&P 500): 97.5% · vs QQQ: 99.8% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +11.9% · vs SPY -2.9% · Prev Value $1.87B — last quarter positions weighted by this quarter price moves · ranking

In its Q2 2024 13F filing, Eversept Partners, LP disclosed 74 equity positions with a combined reported value of $1.46B. The filing implies a focused portfolio: its ten largest positions account for 61.2% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q2 2024 were QQQ ($136.83M), GSK ($133.52M), NTRA ($127.08M). By sector, the heaviest allocations are Health Care 79.6%, Industrials 4.1%. Versus the prior quarter, allocation shifted toward Health Care (+2.3pp) and away from Other (-2.0pp).

Versus the prior quarter, Eversept Partners, LP opened 29 new positions, trimmed 41 and fully exited 27, a turnover rate of 66.4% of positions. The portfolio's overlap with the prior quarter was 67% of names.

The largest new positions opened in Q2 2024 were INSM ($77.42M), XBI ($9.27M), ARQT ($7.79M).

Of the 27 positions fully exited versus the prior quarter, the largest were PFE ($30.58M), SWAV ($26.23M), THC ($18.46M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2024)

  • INSM INSMED INC · $77.42M
  • XBI SPDR SERIES TRUST · $9.27M
  • ARQT ARCUTIS BIOTHERAPEUTICS INC · $7.79M
  • CYTK CYTOKINETICS INC · $6.87M
  • EOLS EVOLUS INC · $6.23M
  • OSCR OSCAR HEALTH INC · $4.92M
  • CERE CEREVEL THERAPEUTICS HLDNG I · $4.50M
  • MYGN MYRIAD GENETICS INC · $4.45M

Fully Exited (vs previous quarter)

  • PFE PFIZER INC · prev qtr: $30.58M
  • SWAV SHOCKWAVE MED INC · prev qtr: $26.23M
  • THC TENET HEALTHCARE CORP · prev qtr: $18.46M · history
  • TARO TARO PHARMACEUTICAL INDS LTD · prev qtr: $11.16M
  • TSHA TAYSHA GENE THERAPIES INC · prev qtr: $6.67M
  • WAT WATERS CORP · prev qtr: $4.69M
  • CRBP CORBUS PHARMACEUTICALS · prev qtr: $3.49M
  • KRYS KRYSTAL BIOTECH INC · prev qtr: $3.30M

Insider Transactions (Form 4)

Latest Eversept Partners, LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Eversept Partners, LP is an SEC-registered 13F filer based in New York, NY, United States. As of Q2 2026 it reported 119 US equity positions with a combined value of $1.91B. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: NEW YORK, NY, United States
  • SEC registration: 801-108771 (status: Approved), registered 2017-01-11
  • Regulatory AUM (Form ADV): $2.65B as of 2026-03-31
  • Client mix (by RAUM): pension and profit-sharing plans 99%, registered investment companies 1%
  • Manages 3 private funds, of which 3 hedge funds
  • Website: eversept.com

Portfolio Structure

  • 119 positions · $1.91B reported value (Q2 2026)
  • Top 10 holdings = 46.1% of reported value
  • Largest position: UTHR (UNITED THERAPEUTICS CORP DEL) at 8.2%
  • Average position size: $16.06M

Sector Tilt

  • Health Care 88.2%
  • Real Estate 5.6%
  • Industrials 1.3%
  • (classified holdings cover 96% of value)

Quarterly Activity

  • Q2 2026: 29 new, 42 added, 41 reduced, 27 exited
  • 7 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 79.6%
Other 13.8%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 285.60K $136.83M 9.37%
9.37%
Reduce
2 3.47M $133.52M 9.14%
9.14%
Reduce
3 1.17M $127.08M 8.70%
8.70%
Reduce
4 1.16M $77.42M 5.30%
5.30%
New
5 4.72M $76.71M 5.25%
5.25%
Reduce
6 235.35K $74.97M 5.13%
5.13%
Reduce
7 3.61M $74.19M 5.08%
5.08%
Add
8 2.04M $73.92M 5.06%
5.06%
Add
9 533.01K $71.33M 4.88%
4.88%
Add
10 451.58K $47.35M 3.24%
3.24%
Reduce
11 135.48K $43.53M 2.98%
2.98%
Add
12 543.04K $38.91M 2.66%
2.66%
Reduce
13 413.53K $35.65M 2.44%
2.44%
Reduce
14 8.04M $27.01M 1.85%
1.85%
Add
15 194.29K $24.49M 1.68%
1.68%
Add
16 633.01K $23.43M 1.60%
1.60%
Reduce
17 456.88K $21.77M 1.49%
1.49%
Add
18 146.96K $20.98M 1.44%
1.44%
Add
19 21.23K $19.22M 1.32%
1.32%
Add
20 505.84K $17.53M 1.20%
1.20%
Add
21 30.80K $16.76M 1.15%
1.15%
Add
22 34.59K $14.88M 1.02%
1.02%
Reduce
23 38.02K $14.21M 0.97%
0.97%
Add
24 1.33M $14.13M 0.97%
0.97%
Add
25 767.66K $14.01M 0.96%
0.96%
Add
26 2.26M $11.78M 0.81%
0.81%
Reduce
27 1.55M $10.56M 0.72%
0.72%
Add
28 40.85K $10.21M 0.70%
0.70%
Hold
29 100.00K $9.27M 0.64%
0.64%
New
30 1.09M $8.97M 0.61%
0.61%
Add
31 14.66K $7.94M 0.54%
0.54%
Add
32 837.85K $7.79M 0.53%
0.53%
New
33 115.82K $7.68M 0.53%
0.53%
Add
34 567.49K $7.38M 0.51%
0.51%
Add
35 138.49K $7.34M 0.50%
0.50%
Add
36 96.09K $7.26M 0.50%
0.50%
Reduce
37 1.15M $7.12M 0.49%
0.49%
Reduce
38 126.88K $6.87M 0.47%
0.47%
New
39 329.89K $6.34M 0.43%
0.43%
Reduce
40 574.46K $6.23M 0.43%
0.43%
New
41 18.28K $5.43M 0.37%
0.37%
Add
42 1.74M $5.10M 0.35%
0.35%
Add
43 5.48M $4.94M 0.34%
0.34%
Reduce
44 310.89K $4.92M 0.34%
0.34%
New
45 110.01K $4.50M 0.31%
0.31%
New
46 373.55K $4.48M 0.31%
0.31%
Reduce
47 181.96K $4.45M 0.30%
0.30%
New
48 1.33M $4.33M 0.30%
0.30%
Reduce
49 4.99M $4.33M 0.30%
0.30%
Reduce
50 1.11M $4.26M 0.29%
0.29%
Reduce

FAQ

What did Eversept Partners, LP buy in 2024-Q2?

In its 2024-Q2 13F filing, Eversept Partners, LP reported 74 equity positions worth $1.46B in aggregate; its largest disclosed positions were QQQ ($136.83M), GSK ($133.52M), NTRA ($127.08M).

How large is Eversept Partners, LP's portfolio?

Eversept Partners, LP reported $1.46B of long equity holdings across 74 positions as of 2024-Q2. Top-10 holdings account for 61.2% of reported value.

What is Eversept Partners, LP's investment style?

HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/eversept-partners/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →